Sharescart Research Club logo

Key Financials Snapshot

TTM · Consolidated · ₹ in Cr
Market Cap
₹4931 Cr.
Stock P/E
45.9
P/B
2.9
Current Price
₹1133.2
Book Value
₹ 388
Face Value
10
52W High
₹1390
52W Low
₹ 944
Dividend Yield
0%

Entero Healthcare Overview

Business

Entero Healthcare Solutions Ltd. operates as a distributor of pharmaceutical and healthcare products in India. Its core business model involves procuring a wide range of products, including medicines, surgicals, medical devices, and other healthcare consumables, directly from manufacturers. It then distributes these products to a diverse customer base, including pharmacies, hospitals, clinics, and other healthcare providers across the country. The company makes money through the margins earned on the sale of these products, leveraging its extensive distribution network, warehousing capabilities, and supply chain management expertise.

Revenue Mix

While specific revenue breakdowns are not provided, healthcare distribution companies typically segment their revenue based on:

Product Categories: Pharmaceuticals (branded generics, generics), Surgical & Medical Devices, Consumer Health Products.

Customer Types: Retail Pharmacies, Hospitals & Institutions, Clinics & Nursing Homes.

Entero is likely to have a significant portion of its revenue derived from the distribution of pharmaceuticals to retail pharmacies, given the large and fragmented nature of this market in India.

Industry

The Indian healthcare distribution industry is vast, complex, and traditionally fragmented, comprising numerous regional and local distributors alongside a few large national players. Entero Healthcare positions itself as one of the larger, organized national distributors, aiming to consolidate market share through scale, technology adoption, and a wide geographical reach. It competes with other large national distributors, smaller regional players, and direct distribution channels employed by some pharmaceutical manufacturers. The industry is characterized by low margins, high volume, and significant working capital requirements.

MOAT

Entero's competitive advantages are likely to stem from:

Scale and Network: An extensive pan-India distribution network, including warehouses, cold chain facilities, and a large sales force, enabling efficient reach to a wide customer base.

Technology Adoption: Investments in supply chain management systems, inventory optimization, and digital platforms to enhance efficiency and reduce costs.

Manufacturer Relationships: Strong, long-standing relationships with a broad portfolio of pharmaceutical and healthcare product manufacturers, ensuring a steady supply of diverse products.

Customer Relationships: A large and loyal customer base built through reliable service, timely delivery, and a comprehensive product offering.

Growth Drivers

Growing Healthcare Expenditure: Increasing healthcare spending in India driven by a rising population, higher disposable incomes, and greater health awareness.

Expansion of Healthcare Infrastructure: Growth in the number of hospitals, clinics, and pharmacies, especially in Tier 2 and Tier 3 cities.

Consolidation of Distribution: The shift from a fragmented, unorganized distribution market towards larger, more efficient national players, which Entero aims to capitalize on.

Increased Product Portfolio: Ability to add new manufacturers and product categories (e.g., specialty medicines, advanced medical devices) to its distribution network.

Digitalization in Healthcare: Leveraging technology for order management, inventory, and logistics to improve efficiency and customer experience.

Risks

Intense Competition & Pricing Pressure: The fragmented nature of the industry leads to high competition, which can put pressure on distribution margins.

Regulatory Changes: Changes in drug pricing policies, distribution licenses, or other healthcare regulations by the Indian government could impact profitability.

Working Capital Management: The business requires significant working capital to manage inventory and credit extended to customers, exposing it to interest rate and credit risks.

Supply Chain Disruptions: Reliance on timely and efficient logistics, making it vulnerable to disruptions in transportation, warehousing, or manufacturing.

Manufacturer Consolidation/Direct Sales: Large manufacturers might consolidate their distribution or increase direct sales, reducing reliance on third-party distributors.

Management & Ownership

Entero Healthcare Solutions Ltd. is promoted by individuals with significant experience in the pharmaceutical distribution sector. The company is likely to be promoter-driven, with key management personnel possessing deep domain expertise in supply chain management and healthcare logistics. Post-IPO, the ownership structure typically involves significant promoter holdings, alongside institutional investors, high net-worth individuals, and public shareholders. The quality of management is critical for navigating the complexities of the Indian distribution market.

Outlook

Entero Healthcare operates in a fundamental yet challenging segment of the Indian healthcare industry. The bull case rests on the immense underlying growth of the Indian healthcare market, the company's established pan-India network, and its potential to gain market share through efficiency and consolidation of the fragmented distribution landscape. Investments in technology and robust supply chain infrastructure can further enhance its competitive edge. The bear case highlights the inherently low-margin nature of the distribution business, intense competition, significant working capital requirements, and potential regulatory interventions that could impact profitability. While the opportunity for organized distributors is substantial, sustained success will depend on efficient operational execution, prudent financial management, and adaptability to evolving market dynamics.

Entero Healthcare Share Price

Live · BSE / NSE · Inception: 2018
| |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Consolidated · annual

Entero Healthcare Quarterly Results

#(Fig in Cr.) Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Net Sales 993 1034 1097 1301 1359 1339 1404 1571 1707 1910
Other Income 2 9 13 11 7 7 6 5 5 4
Total Income 994 1043 1110 1312 1366 1346 1410 1576 1711 1914
Total Expenditure 964 1005 1067 1258 1309 1290 1354 1509 1639 1824
Operating Profit 30 38 44 54 58 56 56 67 72 90
Interest 16 17 10 11 10 10 11 12 14 17
Depreciation 6 7 7 7 8 8 9 10 10 15
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 -8 0
Profit Before Tax 8 14 27 35 39 37 36 45 40 58
Provision for Tax 1 -8 7 9 10 6 6 8 7 13
Profit After Tax 7 21 21 26 29 31 30 37 34 45
Adjustments -0 -0 -0 -2 -4 -6 -2 -5 -6 -17
Profit After Adjustments 7 21 20 24 25 26 28 32 28 28
Adjusted Earnings Per Share 4.2 4.8 4.6 5.4 5.8 5.9 6.4 7.3 6.4 6.4

Entero Healthcare Profit & Loss

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 1780 2522 3300 3922 5096 6592
Other Income 4 4 6 14 40 20
Total Income 1784 2527 3306 3937 5135 6611
Total Expenditure 1758 2498 3236 3810 4924 6326
Operating Profit 25 29 70 126 211 285
Interest 20 29 49 66 42 54
Depreciation 16 20 24 25 31 44
Exceptional Income / Expenses 0 0 0 0 0 -8
Profit Before Tax -11 -20 -4 36 139 179
Provision for Tax 5 10 7 -4 31 34
Profit After Tax -15 -29 -11 40 107 146
Adjustments -0 -0 -0 -1 -13 -30
Profit After Adjustments -16 -30 -12 39 95 116
Adjusted Earnings Per Share -1553.7 -77.7 -28.1 9 21.8 26.5

Entero Healthcare Balance Sheet

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 485 561 595 1638 1724
Minority's Interest 2 2 3 3 46
Borrowings 0 37 31 46 0
Other Non-Current Liabilities 57 63 54 37 73
Total Current Liabilities 289 462 624 602 845
Total Liabilities 833 1125 1307 2326 2688
Fixed Assets 189 262 268 289 559
Other Non-Current Assets 12 12 16 26 53
Total Current Assets 633 851 1023 2011 2076
Total Assets 833 1125 1307 2326 2688

Entero Healthcare Cash Flow

#(Fig in Cr.) Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 43 32 47 25 148
Cash Flow from Operating Activities -69 -35 -45 -37 -77
Cash Flow from Investing Activities -31 -162 -49 -705 220
Cash Flow from Financing Activities 89 211 73 863 -74
Net Cash Inflow / Outflow -11 14 -21 121 69
Closing Cash & Cash Equivalent 32 47 25 148 229

Entero Healthcare Ratios

# Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) -1553.7 -77.71 -28.11 8.99 21.79
CEPS(Rs) 92.2 -25.16 31.94 14.9 31.75
DPS(Rs) 0 0 0 0 0
Book NAV/Share(Rs) -3174.6 -150.52 -166.8 376.21 395.31
Core EBITDA Margin(%) 1.21 0.97 1.94 2.85 3.37
EBIT Margin(%) 0.52 0.36 1.37 2.58 3.54
Pre Tax Margin(%) -0.61 -0.79 -0.11 0.91 2.72
PAT Margin (%) -0.86 -1.17 -0.34 1.01 2.11
Cash Profit Margin (%) 0.05 -0.38 0.4 1.65 2.71
ROA(%) -1.84 -3.01 -0.91 2.19 4.29
ROE(%) 0 0 0 5.08 6.4
ROCE(%) 1.47 1.24 4.99 7.02 9.16
Receivable days 49.66 44.63 49.19 52.59 51.78
Inventory Days 50.03 40.09 36.04 35.49 38.71
Payable days 21.55 18.67 21.08 22.51 24.83
PER(x) 0 0 0 109.53 52.15
Price/Book(x) 0 0 0 2.62 2.88
Dividend Yield(%) 0 0 0 0 0
EV/Net Sales(x) 0.32 0.32 0.28 0.93 0.98
EV/Core EBITDA(x) 22.61 27.75 13.45 29.04 23.61
Net Sales Growth(%) 0 41.71 30.85 18.85 29.92
EBIT Growth(%) 0 -0.36 393.99 123.56 78.15
PAT Growth(%) 0 -91.74 62.28 458.42 169.94
EPS Growth(%) 0 95 63.83 131.99 142.37
Debt/Equity(x) 0.29 0.51 0.63 0.17 0.17
Current Ratio(x) 2.19 1.84 1.64 3.34 2.46
Quick Ratio(x) 1.35 1.17 1.09 2.64 1.68
Interest Cover(x) 0.46 0.32 0.92 1.54 4.33
Total Debt/Mcap(x) 0 0 0 0.06 0.06

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +30% +26%
Operating Profit CAGR +67% +94%
PAT CAGR +168%
Share Price CAGR -6%
ROE Average +6% +4% +2% +2%
ROCE Average +9% +7% +5% +5%

Entero Healthcare Shareholding Pattern

Latest · Mar 2026
100% held
Promoters 52.42 %
FII 4.03 %
DII (MF + Insurance) 16.62 %
Public (retail) 47.58 %
# Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Promoter 52.4452.4452.4452.4452.4252.4252.4252.4252.42
FII 23.323.3223.8222.2119.9217.214.675.144.03
DII 2.282.067.738.779.6410.189.6516.4216.62
Public 47.5647.5647.5647.5647.5847.5847.5847.5847.58
Others 000000000
Total 100100100100100100100100100

Entero Healthcare Peer Comparison

Entero Healthcare Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Entero Healthcare Pros & Cons

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Company has a low return on equity of 4% over the last 3 years.
  • Debtor days have increased from 22.51 to 24.83days.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp